Borenius advised Nightingale Health Plc on its Nasdaq First North Growth Market Finland IPO

We advised Nightingale Health Plc on its EUR 110 million initial public offering (IPO) to Nasdaq First North Growth Market Finland. Nightingale Health’s IPO is the largest Finnish First North IPO to date, and trading on the company’s shares began on 19 March 2021. Advokatfirman Vinge KB and Kromann Reumert acted as our co-counsel for Nightingale on matters concerning Swedish and Danish law.

Nightingale Health is a Finnish health technology company that is seeking to transform preventive care. The company’s mission is to bring disease prevention and healthier life within everyone’s reach. By combining their pioneering blood-testing technology and the ability to detect future disease risks, Nightingale is creating a world-leading health data platform that enables preventive care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs.

By empowering the world with comprehensive health insights, Nightingale accelerates scientific discoveries and industry developments in addition to improving personal health for everyone.